目的 探讨小儿治哮灵片联合丙酸倍氯米松治疗儿童支气管哮喘急性发作期的临床疗效。方法 收集2023年6月—2025年9月宝鸡市人民医院接诊的支气管哮喘急性发作期患儿126例，通过随机信封法分为对照组（63例）和治疗组（63例）。对照组患儿雾化吸入吸入用丙酸倍氯米松混悬液，0.4～0.8 mg/次，2次/d；治疗组在对照组基础上口服小儿治哮灵片，6片/次，3次/d。两组患儿均接受连续2周治疗。观察两组患儿的临床疗效，对比临床症状改善时间，治疗前后肺功能指标第1秒用力呼气容积（FEV1）、用力肺活量（FVC）、每分钟最大通气量（MVV）、呼气峰值流速（PEF）、FEV1/FVC，气道炎症指标诱导痰嗜酸性粒细胞（EOS）计数、呼出气一氧化氮（FeNO）。结果 治疗后，相较于对照组的总有效率（84.13%），治疗组总有效率（95.24%）显著更高（P＜0.05）。此外，治疗组患儿各临床症状的改善时间亦明显短于对照组（P＜0.05）。与治疗前相比，两组患儿FEV1、FVC、MVV、PEF和FEV1/FVC均明显升高，而EOS计数和FeNO水平均显著降低（P＜0.05），与此同时，治疗组患儿肺功能相关指标及气道炎症指标的改善效果均明显优于对照组（P＜0.05）。结论 小儿治哮灵片联合丙酸倍氯米松应用于儿童支气管哮喘急性发作期的治疗，临床疗效确切，不仅能有效缩短症状缓解时间，还可明显改善患儿肺功能及气道炎症状态，且安全性良好。

Objective To explore the clinical efficacy of Xiaoer Zhixiaoling Tablets combined with beclomethasone propionate in the treatment of acute exacerbation of bronchial asthma in children. Methods A total of 126 children with acute bronchial asthma exacerbation admitted to Baoji People’s Hospital from June 2023 to September 2025 were enrolled and divided into control group and treatment group by random envelope method, with 63 cases in each group. Children in the control group received nebulized inhalation of beclomethasone propionate suspension for inhalation at 0.4 — 0.8 mg twice daily. On the basis of the identical conventional treatment, the treatment group was additionally administered oral Xiaoer Zhixiaoling Tablets at a dose of six tablets three times daily. Both groups received continuous treatment for two weeks. The overall clinical efficacy and symptom remission time were compared. Pulmonary function parameters, including forced expiratory volume in the first second (FEV1), forced vital capacity (FVC), maximal voluntary ventilation (MVV), peak expiratory flow (PEF), and FEV1/FVC ratio, as well as airway inflammatory indicators including induced sputum eosinophil (EOS) count and fractional exhaled nitric oxide (FeNO), were evaluated before and after treatment. Results After treatment, the treatment group achieved a significantly higher overall effective rate than the control group (95.24% vs 84.13%, P< 0.05). The remission time of clinical symptoms was markedly shorter in the treatment group (P < 0.05). Both groups presented significant improvements in pulmonary function and reductions in airway inflammation after intervention (P< 0.05). Specifically, FEV1, FVC, MVV, PEF and FEV1/FVC were substantially increased, while EOS count and FeNO levels were prominently decreased in both groups. Furthermore, the treatment group exhibited superior improvements in all pulmonary function and inflammatory biomarkers compared with the control group (P < 0.05). Conclusion The combination of Xiaoer Zhixiaoling Tablets and beclomethasone propionate exerts promising clinical efficacy for children with acute asthma exacerbation. This combined regimen effectively shortens symptom relief duration, improves pulmonary function, and alleviates airway inflammatory responses with a favorable safety profile, supporting its clinical application in pediatric asthma management.

R974;R985

陕西省保健学会药学服务科研基金资助项目（KY-2023-01-YX-07）